Oral anticoagulation therapy is currently undergoing great changes with the development
and use of several new medications. The newer drugs have a more specific mechanism of …

Conventional prothrombin time (PT) assays have limited sensitivity and dynamic range in
monitoring the anticoagulant activity of direct factor Xa inhibitors. Hence, new assays are …

Thrombosis and Haemostasis in which the authors investigated the anti-Xa assays and the
prothrombin time (PT) test for their suitability to measure the anticoagulant effect of newly …

Novel oral anticoagulants, direct thrombin inhibitors, and factor Xa inhibitors are being
introduced into clinical practice. In contrast to vitamin K antagonists, such as warfarin, these …

Background Direct oral anticoagulants targeting factor Xa (DXaIs) are administered as
prophylaxis for various venothrombotic diseases without routine monitoring required …

New oral anticoagulants which specifically inhibit factor Xa (FXa) or thrombin (FIIa) do not
require routine laboratory monitoring. However, they induce a state of hypocoagulation and …

Although the non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine
monitoring, there are special circumstances in which laboratory measurement may be …

The introduction of several oral direct anticoagulants within the past 2–3 years has
dramatically changed clinical practice and has also impacted on utilization and …

Thromboembolic diseases require anticoagulation for their prevention and treatment. New
oral anticoagulants, specifically direct factor Xa and thrombin inhibitors, were developed to …

Although direct oral anticoagulants do not need laboratory testing for dose adjustment, there
are instances when laboratory measurement of the drug anticoagulant effect may be useful …